compounding pharmacies tirzepatide FDA says can keep making weight-loss med tirzepatide, for now FDA ban on compounded tirzepatide:

It is suitable for patients with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher who have additional health concerns related to their weight

These studies suggest that retatrutide is a promising advancement in obesity and diabetes treatment, especially for patients needing significant weight loss and improved glycaemic control

Dysregulation of Adipose Glutathione Peroxidase 3 in Obesity Contributes to Local and Systemic Oxidative Stress

Among firms offering health benefits, 4% believe that their employees level of concern over the difficulty of finding in-network providers is high, 13% believe the level of concern is moderate, 42% believe the level of concern is low, 35% believe the level of concern is none, and 5% do not know the level of concern

Staying hydrated is critical